French-based biopharmaceutical company Cellectis has treated the first patient in the Phase I trial of its UCART19 to treat pediatric acute B lymphoblastic leukemia (B-ALL).

UCART19 is the company’s allogeneic CAR T-cell product candidate, developed to treat CD19-expressing hematological malignancies and gene edited with TALEN®.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

TALEN® is a monomeric compact product based on Cellectis’ patented TAL effector nuclease technology. It requires the expression of only one DNA or RNA molecule to be active.

The open label, non-comparative and single-centre pediatric Phase I trial is sponsored by Servier in close collaboration with Pfizer.

"UCART19 is initially being developed in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL)."

It is designed to assess the safety and efficacy of UCART19 to facilitate molecular remission in pediatric patients afflicted with elapsed or refractory CD19, positive B-cell, acute lymphoblastic leukemia ahead of planned allogeneic haematopoeitic stem-cell transplantation (allo-HSCT).

See Also:

UCART19 is initially being developed in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initial clinical trials of UCART19 using autologous products based on the CAR technology has demonstrated the ability to overcome the limitations of the current autologous method by offering an allogeneic, frozen, off-the-shelf T cell based medicinal product.

Servier has assumed the exclusive rights for UCART19 from Cellectis, while Pfizer has secured exclusive rights from Servier to develop and market the product in US.

After further agreements, Servier and Pfizer has started cooperating on a joint clinical development programme for Cellectis’ cancer immunotherapy.